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Abstract
Background: Osteochondroma generally occurs as a single lesion and it is not a heritable disease. When two or
more osteochondroma are present, this condition represents a genetic disorder named hereditary multiple
exostoses (HME). Growth hormone deficiency (GHD) has rarely been found in HME patients and a few data about
growth therapy (GH) therapy effects in development/growth of solitary or multiple exostoses have been reported.
Case presentation: We describe the clinical features of 2 patients (one with osteochondroma and one with HME)
evaluated before and after GH therapy. In the first patient, the single osteochondroma was noticed after the start of
treatment; the other patient showed no evidence of significant increase in size or number of lesions related to GH
therapy.
Conclusion: It is necessary to investigate GH secretion in patients with osteochondroma or HME and short stature
because they could benefit from GH replacement therapy. Moreover, careful clinical and imaging follow-up of
exostoses is mandatory.
Background
Solitary osteochondroma occurs as a sporadic event and it
is known to be a non-genetic condition. Osteochondromas
account for about 30 % of benign bone tumours and they
grow slowly in skeletally immature individuals, while the
increase in size of this lesion in adult patients is considered
an indication of malignant transformation [1].
Hereditary multiple exostoses (HME) is an autosomal
dominant heritable disorder, characterized by the formation
of multiple osteochondromas: these lesions can increase in
number and size during skeletal development [2] and stop
growing with skeletal maturity, after which no new osteo-
chondromas develop. Exostoses are rarely evident at birth
[3] and the age of onset is variable, from 2 to 15 years [4].
Clinical expression of HME phenotype is variable in indi-
viduals, also in the same family [5, 6]. The majority of HME
or solitary osteochondroma patients are asymptomatic.
Osteochondromas are located in bones that develop from
cartilage, especially the long bones of the extremities, pre-
dominantly around the knee. Osteochondromas can cause
deformities, bursa formation, arthritis and impingement
on adjacent tendons, nerves, vessels [3–5, 7]. However,
the most serious complication is the malignant transform-
ation towards a rare form of bone cancer called chondro-
sarcoma, described in adulthood with variable incidence
in different series, but still in a small percentage in HME
patients (0.5-5 %) [5, 8]. Solitary osteochondroma malig-
nant transformation is estimated in about 1-2 % [9].
HME is caused by mutations in two genes, EXT1 (MIM
*608177) and EXT2 (MIM *608210) [5, 10, 11]; however, in
some families no mutations in EXT1 and EXT2 genes are
detected, suggesting involvement of other genes in the
pathogenesis of the disease. While most patients have an af-
fected parent, in other cases patients carry a de novo muta-
tion. EXT1 and EXT2 proteins are ubiquitously expressed
transmembrane proteins, which form heterodimers. These
proteins are involved in heparan sulfate (HS) elongation
and related to signal transduction cascade for regulation of
chondrocyte differentiation, ossification, and apoptosis [12].
* Correspondence: mauro.bozzola@unipv.it
1Internal Medicine and Therapeutics Department, Pediatric and Adolescent
Unit, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Piazzale
Golgi, 2, 27100 Pavia, Italy
Full list of author information is available at the end of the article
ITALIAN JOURNAL
OF PEDIATRICS
© 2015 Bozzola et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bozzola et al. Italian Journal of Pediatrics  (2015) 41:53 
DOI 10.1186/s13052-015-0162-2
On the contrary, solitary osteochondroma somatic muta-
tions in the EXT1 gene, are extremely rare [10].
In comparison with the reference healthy population
and patients’ parents or sibs, a shorter stature has been
reported in some HME patients [13], but in other studies
most adults with EXT2 mutations and many with EXT1
mutations fall within the normal range [14]. Pedrini and
colleagues described a correlation between reduced height
and clinical severity of disease, and patients with no
detectable EXT1 or EXT2 mutation had a nearly normal
height in this series [8]. Further studies are needed to
confirm the incidence of short stature in HME patients.
In the present study, we collected data about the clinical
follow-up of HME and solitary osteochondroma patients
with growth hormone deficiency (GHD) who underwent
GH therapy; in particular, we investigated their response
to therapy and the effects on osteochondroma develop-
ment and growth, observing the bone lesions before and
during GH treatment. Furthermore, the question whether
the occurrence and/or increase of the exostoses may be
related to GH treatment or to the normal evolution of this
bone disease is debated.
Case presentation
We followed two GHD children (one boy and one girl).
GHD was established, after excluding other causes of
growth failure, on the basis of short stature, reduced growth
rate, delayed bone age and insufficient GH response to at
least two classic pharmacological stimuli (peak <10 ng/ml),
according to international guidelines in force at that time
[15]. Recombinant hGH was administered by daily subcuta-
neous injections, in according to national rules for the use
of GH [16]. GH replacement treatment was monitored
every six months by evaluating anthropometric and labora-
tory parameters (i.e. insulin-like growth factor-I (IGF-I)
levels, A1c fraction of glycosylated haemoglobin, adrenal
and thyroid function), and assessing compliance.
Patient 1 was born by spontaneous vaginal delivery at the
38th week of an uncomplicated pregnancy and he was the
fourth child of non-consanguineous parents. Birth length
was 52 cm and birth weight 3,200 g. Perinatal period and
neuropsychological development were normal. Scholastic
performance and physical activity were normal, too. The
patient was first referred to the Paediatric department at
the age of 13 years and 9 months because of slight short
stature (150 cm, -1.11 SDS). He showed a weight of 34 Kg
(BMI 15.11 kg/m2, -2.0 SDS), a reduced growth rate (4 cm/
year; -4.0 SDS), a delayed bone age (11 years) and gonadal
volume of 3.5 ml (pre-pubertal stage). Genetic target was
181.75 cm (1.1 SDS). Hypothyroidism, chronic diseases,
malabsorption including celiac disease and skeletal
dwarfism were excluded. GH deficiency was diagnosed
by two classic stimulation tests such as arginine infu-
sion (GH peak: 6.8 ng/ml) and glucagon administration
(GH peak: 6.1 ng/ml) and confirmed by low serum
IGF-I values (132 ng/ml; -3.19 SDS). The MRI of the
hypothalamic-pituitary region showed major abnormal-
ities including reduced size of the pituitary gland and
the thickening of the pituitary stalk, but normal appear-
ance of neurohypophysis. A replacement therapy with
GH (0.21 mg/Kg/week divided in 6 doses) showed a good
response on linear growth: 6.58 cm (1.23 SDS) during the
first year and 6.80 cm (5.08 SDS) during the second year of
therapy. At the age of 15 years and 7 months, i.e. 1.5 years
after the beginning of GH treatment, a cartilage-capped pe-
dunculated solitary osteochondroma (12 mm) on the med-
ial margin of the third proximal of the right tibial diaphysis
in communication with two small solid palpable cartilagin-
ous formations (15×18 mm and 8×5 mm) was observed
(Fig. 1). The orthopaedist decided to immediately stop GH
therapy because he was afraid of any influence on the exo-
stoses. Since no macroscopic increase of the exostoses was
observed after 4 months, the patient’s parents requested
that the replacement therapy be started again. The patient
grew 7.4 cm more and decided to stop GH therapy at the
age of 18 years when he reached a height of 177.4 cm [0.41
SDS], although skeletal maturity was not achieved. After
stopping the treatment, right leg X-rays showed an in-
creased size of the pedunculated exostoses on the medial
margin of the third proximal of the right tibial diaphysis
(31×20.5 mm) (Fig. 2) compared to previous radiographs
performed during the treatment (20.2×16.6 mm) in com-
munication with other palpable cartilaginous formations
(11.6×8.2 mm, 8.5×7 mm, 17×10 mm) of increased size
compared to previous radiographs.
The family history in this case is peculiar, because
other family members had solitary osteochondromas.
The proband’s older brother (23 years old) had a soli-
tary osteochondroma on the same side as the proband.
Bilateral X-rays of knee, ankle and hand did not show
further exostoses and no other lesions have been
reported. Exostoses was revealed at the age of 13 years
and slightly increased 5 years later. X-rays in both par-
ents performed for traumatic events did not show
osteochondromas. It was reported that both the pater-
nal grandmother and the maternal grandfather had the
same solitary osteochondroma as the proband’s brother
(no clinical reports available). The 24-years-old sister
showed a bone protuberance on the sole of the right
foot, painful during exercise, while the younger sister,
aged 21, showed no visible exostoses. A first cousin of
the proband underwent treatment for a brief period for
GH deficiency, but at the age of 19 years her height
was reported to be about 160 cm (-0.59 SDS). Because
of the unusual recurrence of the lesion in other family
members, EXT1 and EXT2 molecular analysis was per-
formed in the proband: no sequence variants or dele-
tion were detected.
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Patient 2 was a girl affected by HME who came to our
attention when she was 3 years and 3 months old. Height
was 95 cm (-0.05 SDS), weight 12.5 Kg (BMI 13.85 kg/m2, -
1.38 SDS). She had small osteochondromas (scapulae, ribs,
left distal femur, right proximal tibia, left forearm) at clinical
examination. Family history was positive for the disease: the
father and the younger sister were also affected. She was
born by spontaneous vaginal delivery at term of an uncom-
plicated pregnancy. Birth weight was 2,880 g. Perinatal
period and neuropsychological development were normal.
Genetic target was 158.5 (-0.7 SDS). The child underwent
regular orthopaedic follow-up in particular to evaluate the
larger forearm exostoses for surgical removal. Furthermore,
she had diagnosis of Langerhans cell histiocytosis at the age
of 3 years and 6 months. She also had a follow-up and ther-
apy for diabetes insipidus (Minirin 0.075 mg twice day). At
the age of 5 years and 5 months auxologic parameters
were: height 104 cm (-1.22 SDS) and weight 17 Kg (BMI
15.72 kg/m2, -0.09 SDS). Therefore an endocrinological
evaluation was started. Clonidine test showed a GH peak
of 3.6 ng/ml, arginine test results showed a GH peak of
1.7 ng/ml; IGF-I levels were 66 ng/ml (-1.62 SDS). The
MRI of the hypothalamic-pituitary region showed the
thickening of the pituitary stalk (4.18 mm) and normal
appearance of anterior pituitary, with the absence of the
neurohypophysis bright spot. At age of 6 years she started
GH replacement treatment at a standard dose of 0.24 mg/
kg/week. Before starting GH therapy an ultrasound exam-
ination of the osteochondromas was performed. After the
first year of treatment growth velocity was 9.5 cm/year (5.9
SDS) and her height was 118 cm (-0.72 SDS). During the
second and third year of GH treatment growth velocity
decreased to 1.8 and 2.1 SDS, respectively. At 6, 12 and
18 months after the treatment, ultrasound evaluation
showed no major modifications of exostoses, but only a
mild thickening of the left ulnar and humeral exostoses
cartilaginous cap after 18 months. Molecular analysis iden-
tified EXT1 mutation (c.1019G >A; p.R340H), previously
found in her father.
Discussion and conclusions
Osteochondromas are one of the most common benign
bone tumours slowly growing in skeletally immature
individuals. In adult patients, the increase in size of an
osteochondroma is considered an indication of malig-
nant transformation. On the other hand, spontaneous
disappearance of exostoses in childhood or puberty has
been reported [1, 17], but during skeletal development
the appearance of new lesions or increased size are a
part of the natural history of HME. In a large series of
patients, a few genotype-phenotype correlations have
been described [8]. Actually, HME is a disease with wide
Fig. 1 Patient 1 right leg X-rays during GH treatment
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inter- and intra-familial clinical variability, so age of
onset, number, size and localization of osteochondromas
cannot be predicted on molecular bases.
Because of growth plate involvement, a correlation be-
tween growth defect and HME or solitary osteochondroma
has been suggested. The growth plate is responsible for lon-
gitudinal bone growth and chondrocytes play a role in bone
elongation. Chondrocytes function in growth plate and
bone growth is tightly regulated by circulating molecules
(i.e. GH) and locally secreted factors (in part by chondro-
cytes) and extracellular matrix (ECM) components (includ-
ing HS/proteoglycans) are part of the intricate growth plate
biology [18]. It has been suggested that osteochondroma
development is due to abnormal HS-dependent signalling
pathways and related to increased environment factors
inducing proliferation in growth plate [19]. The molecular
bases of many chondrodysplasias, chondrocytes and ECM
components detailed role in all involved signalling pathways
in growth plate are not completely understood and further
studies are in progress [20]. Because of the GH effect on
growth plate biology and chondrocyte proliferation, it could
be possible that GH could stimulate osteochondroma
development, but no strong evidence has been reported
from large patient series.
Whereas short stature has been reported in several stud-
ies involving HME patients [6, 13], GH deficiency and GH
replacement therapy have not been well described in this
disease. Lazaro Martinez reported a patient affected by
HME and short stature due to GH deficiency who was
treated with GH. Owing to the occurrence of an inappro-
priate growth of the upper extremities and a worsening of
the cervical exostoses without pain and functional impair-
ment, GH therapy was interrupted after 1 year [21]. Galasso
and colleagues reported a patient with HME and partial
GH deficiency treated for four years. GH replacement ther-
apy was discontinued because of a poor linear growth
response and a moderate increase in size of the exostoses.
However, the diagnosis of GH deficiency was not confirmed
by a third test [22]. Both the authors concluded that a care-
ful follow-up in these patients is mandatory, even if no
evidence of adverse effects on disease course was proven in
their two patients.
In our patient 1, it was difficult to establish whether the
increase of the osteochondroma was due to GH therapy or
to the normal evolution of this bone disease. However, the
increased size of the exostoses in our GH-treated patient
and his untreated brother suggests that age, especially pu-
berty, could be the major factor affecting the evolution of
these curious bone lesions. Furthermore, this patient had a
familial history of osteochondroma but no alterations have
been identified in the EXT1 and EXT2 genes. We could
hypothesize that the familial recurrence of osteochondroma
Fig. 2 Patient 1 right leg X-rays after GH treatment
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could be related to an altered and still unknown genetic
background.
In the HME patient (patient 2), no evident increase in
size or number of lesions was observed. Moreover, since
these lesions tend to increase with age, we are not able to
confirm or not if GH treatment could modify the natural
course of the disease, inducing growth of existent lesions
or new lesion development, since the patient is now at
18 months of treatment.
These data are not conclusive about the effects of GH
therapy on the lesions, but they can be preliminary for a
larger observational study to define whether this treatment
worsens the natural course of the disease or not. Since to
the best of our knowledge there is no evidence of either in-
creased growth or development of osteochondroma due to
GH therapy and evidence of negative effects of the therapy
in both patients with osteochondroma and HME, a closer
follow-up is mandatory during GH replacement therapy, in
particular in those with osetochondroma since the most
serious complication of osteochondromas is the malignant
transformation towards chondrosarcoma [5]. In fact, it has
recently been found a 5 times more bone tumour-related
deaths than expected in adults treated with GH during
childhood [23]. Such an effect is biologically plausible
because these tumours mostly occur during phases of rapid
bone growth, seem to be related to height, and are related
to the IGF-I system [24, 25].
In conclusion, it is necessary to investigate GH secretion
in both patients with solitary osteochondroma and HME
and short stature, because when GH deficiency is con-
firmed by clinical features and classic pharmacological tests,
GH replacement therapy could be started to improve their
stature. Moreover, a close follow-up of exostoses and HME
before and during a long-term GH treatment is mandatory,
in particular in patients with osteochondorma which could
transformate into chondrosarcoma. However, studies with a
longer follow-up are needed in order to define long-term
effects of GH treatment on osteochondromas.
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